Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Jan. 25, 2016

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

Jan. 25, 2016

ImmunID to apply its ImmunTraCkeR assay to phase II trial of IRX-2 in HNSCC

Jan. 22, 2016

FDA approves sBLA for Arzerra as extended treatment of recurrent or progressive CLL

Jan. 21, 2016

Mologen and MD Anderson collaborate in trial of lefitolimod + ipilimumab

Jan. 20, 2016

Bayer Schering Pharma announces BUB1 inhibitors

Jan. 15, 2016

FDA grants orphan drug designation to FPA-008 for pigmented villonodular synovitis

Jan. 14, 2016

Bellicum seeks NIH RAC approval to start clinical trials of TCR therapies

Jan. 13, 2016

FDA grants orphan drug designation for WT1 cancer vaccine for the treatment of AML

Jan. 12, 2016

FDA grants orphan drug designation to components of Immune Design's CMB-305

Jan. 11, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...